These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22152421)

  • 1. [Bringing evidence to practice: obstacles and barriers].
    Niebling W
    Z Evid Fortbild Qual Gesundhwes; 2011; 105(9):646-51. PubMed ID: 22152421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug testing. Massive trial of Celebrex seeks to settle safety concerns.
    Couzin J
    Science; 2005 Dec; 310(5756):1890-1. PubMed ID: 16373546
    [No Abstract]   [Full Text] [Related]  

  • 3. [Financial interests characterize published reports on coxiber. Whom can we rely on?].
    Håkansson J
    Lakartidningen; 2002 Oct; 99(40):3930-1. PubMed ID: 12422746
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celecoxib and the CLASS trial: data massaging by industry.
    Prescrire Int; 2002 Dec; 11(62):190-1. PubMed ID: 12472103
    [No Abstract]   [Full Text] [Related]  

  • 7. [Study results of routine clinical practice. Do rheumatism patients get substandard care?].
    MMW Fortschr Med; 2005 Nov; 147(47):63. PubMed ID: 16370199
    [No Abstract]   [Full Text] [Related]  

  • 8. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digging for data from the COX-2 trials.
    McCormack JP; Rangno R
    CMAJ; 2002 Jun; 166(13):1649-50. PubMed ID: 12126315
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to Ray and colleagues: the called-for large clinical trial is already ongoing.
    Peura D; Chan FK; Wilcox CM; Niculescu L; Berger M
    Gastroenterology; 2008 Jan; 134(1):370-1; author reply 371. PubMed ID: 18166374
    [No Abstract]   [Full Text] [Related]  

  • 11. Research Ethics . In clear sight.
    de Andrade M
    BMJ; 2009 Sep; 339():b3443. PubMed ID: 19726462
    [No Abstract]   [Full Text] [Related]  

  • 12. [Closing evidence gaps].
    Lange S
    Z Evid Fortbild Qual Gesundhwes; 2011; 105(9):652-6. PubMed ID: 22152422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of celecoxib compared with diclofenac slow release in the treatment of acute ankle sprain in an Asian population.
    Nadarajah A; Abrahan L; Lau FL; Hwang LJ; Fakir-Bolte C
    Singapore Med J; 2006 Jun; 47(6):534-42. PubMed ID: 16752024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
    Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
    Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effective also in Bechterew disease].
    MMW Fortschr Med; 2007 Jun; 149(25-26):46-7. PubMed ID: 17713052
    [No Abstract]   [Full Text] [Related]  

  • 16. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease.
    Korzenik JR; Podolsky DK
    Clin Gastroenterol Hepatol; 2006 Feb; 4(2):157-9. PubMed ID: 16469674
    [No Abstract]   [Full Text] [Related]  

  • 18. NSAIDs, Helicobacter pylori, and Pandora's Box.
    Graham DY
    N Engl J Med; 2002 Dec; 347(26):2162-4. PubMed ID: 12501230
    [No Abstract]   [Full Text] [Related]  

  • 19. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
    Patterson MK; Castellsague J; Walker AM
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):982-8. PubMed ID: 18711705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.